Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

995 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM. Long GV, et al. Among authors: dummer r. N Engl J Med. 2017 Nov 9;377(19):1813-1823. doi: 10.1056/NEJMoa1708539. Epub 2017 Sep 10. N Engl J Med. 2017. PMID: 28891408 Free article. Clinical Trial.
[Cutaneous lymphoma].
Hauschild A, Dummer R, Sterry W. Hauschild A, et al. Among authors: dummer r. Dtsch Med Wochenschr. 1996 Oct 25;121(43):1335-40. doi: 10.1055/s-2008-1043149. Dtsch Med Wochenschr. 1996. PMID: 8964215 Review. German. No abstract available.
Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, Dummer R, Ugurel S, Sebastian G, Nashan D, Linse R, Achtelik W, Mohr P, Kaufmann R, Fey M, Ulrich J, Tilgen W. Hauschild A, et al. Among authors: dummer r. Br J Cancer. 2001 Apr 20;84(8):1036-42. doi: 10.1054/bjoc.2001.1731. Br J Cancer. 2001. PMID: 11308250 Free PMC article. Clinical Trial.
Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin.
Keilholz U, Martus P, Punt CJ, Kruit W, Mooser G, Schadendorf D, Liénard D, Dummer R, Koller J, Voit C, Eggermont AM. Keilholz U, et al. Among authors: dummer r. Eur J Cancer. 2002 Jul;38(11):1501-11. doi: 10.1016/s0959-8049(02)00123-5. Eur J Cancer. 2002. PMID: 12110497 Clinical Trial.
Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis.
Hauschild A, Weichenthal M, Balda BR, Becker JC, Wolff HH, Tilgen W, Schulte KW, Ring J, Schadendorf D, Lischner S, Burg G, Dummer R. Hauschild A, et al. Among authors: dummer r. J Clin Oncol. 2003 Aug 1;21(15):2883-8. doi: 10.1200/JCO.2003.07.116. J Clin Oncol. 2003. PMID: 12885805 Clinical Trial.
995 results